Alan Bash describes Legend Biotech as a 'Goldilocks company.' It has an approved, blockbuster therapy, a strong balance sheet, and a pipeline, providing stability. Yet, it maintains a small, agile culture focused on fast decision-making, offering the best of both worlds.
Contrary to the belief that CAR-T therapies require inpatient hospitalization, about 50% of Carvykti infusions occur in an outpatient setting. This flexibility allows more hospitals to offer the treatment and makes it more accessible for patients, revolutionizing the delivery model for complex cell therapies.
Alan Bash's biggest learning after moving from Bristol-Myers Squibb to smaller biotechs was the constant pressure of cash runway. Unlike in large pharma where budgets are a concern, in biotech, cash availability dictates all strategic choices, including partnerships and M&A.
At Zeal Bio, Alan Bash recommended shutting down operations when the science failed to show sufficient conviction for investors. This tough but pragmatic decision, made sooner rather than later, was respected by investors as it prevented further capital loss on a non-viable program.
Scaling manufacturing and commercialization for an autologous CAR-T therapy like Carvykti is too complex for a small biotech alone. Legend Biotech's partnership with J&J was critical, combining Legend's science with J&J's global manufacturing, clinical development, and commercial muscle.
J&J overcame skepticism about Legend's impressive but China-based CAR-T data by conducting deep, on-the-ground due diligence. They reviewed patient records and documentation to confirm the data's integrity, which became the foundation for a highly successful global partnership.
In a crowded multiple myeloma market, treatment sequencing is critical. The International Myeloma Working Group (IMWG) recommends using BCMA CAR-T therapies like Carvykti before BCMA bispecifics. This guidance helps defend Carvykti's position, as prior bispecific use may reduce CAR-T efficacy.
As competitors enter the market with clinical data from just a few hundred patients, Legend Biotech's key differentiator is its extensive real-world experience. Having treated 10,000 patients gives physicians confidence in Carvykti's efficacy and safety profile, which curated trial data cannot replicate.